Clinical trial
Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and…
NCT00053937 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00053937 |
|---|---|
| Title | Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas |
| Official title | Phase I Trial Of Pirfenidone In Children With Neurofibromatosis Type 1 And Plexiform Neurofibromas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neurofibromatosis Type 1, Precancerous Condition |
| Intervention type | Drug |
| Interventions | pirfenidone |
| Start date | Dec 1, 2002 |
| First posted | Feb 6, 2003 |
| Last update posted | Apr 30, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: